ARMO Initiates Phase I trial of AM0010

Will establish safety and tolerability in patients with advanced solid tumors

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

ARMO BioSciences has initiated the first cohort of patients with advanced solid tumors in a Phase I trial of AM0010, a PEGylated form of recombinant human interleukin-10 (IL-10). Based on clinical and preclinical data, ARMO plans to develop the drug for indications including cancer, fibrosis, hypercholesterolemia/atherosclerosis and inflammatory diseases.  The Phase I trial is designed to establish the safety and tolerability of AM0010 in patients with advanced solid tumors. The company will al...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters